Lilly lowers 2019 forecast due to drug failure, pending deal
Shares of Eli Lilly slipped in early trading Wednesday after the drugmaker announced fourth-quarter earnings that missed Wall Street expectations and dropped its forecast for 2019.
More from Minnesota Business
Star Tribune Business
Ramstad: Fraud in Minnesota has not cost $9 billion, but it's hurt more
Minnesota Business
•
3h ago
Star Tribune Business
Summit Brewing could avoid foreclosure with new lender
Minnesota Business
•
1d ago
Star Tribune Business
Watch the replays of the North Star Summit sessions
Minnesota Business
•
1d ago
Star Tribune Business
Social Security recipients to get 3.6% cost of living boost, an average of $75 per month
Minnesota Business
•
2d ago